Sign In
Buy OPY
$106.64
-4.06 (-3.67%)
At Close: Jul 31, 2026
Oppenheimer (OPY) Q2 Net Income Doubles
03:42am, Saturday, 02'nd Aug 2025
Oppenheimer (OPY) Q2 Net Income Doubles
Oppenheimer Holdings Inc. Reports Second Quarter 2025 Earnings
08:00am, Friday, 01'st Aug 2025
NEW YORK , Aug. 1, 2025 /PRNewswire/ - Oppenheimer Holdings Inc. (NYSE: OPY) (the "Company" or "Firm") today reported net income of $21.7 million or $2.06 basic earnings per share for the second quart
Oppenheimer's Jason Helfstein: Meta is showing they can use AI to drive higher engagment
11:22am, Thursday, 31'st Jul 2025
Jason Helfstein, Oppenheimer analyst, joins CNBC's 'Squawk on the Street' to discuss outlooks on tech stocks, expectations for earnings, and much more.
Gilat to Present at the 28th Annual Oppenheimer Technology, Internet & Communications Virtual Conference on Monday, August 11
07:02am, Thursday, 31'st Jul 2025
PETAH TIKVA, Israel, July 31, 2025 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, today a
Oppenheimer's Jason Helfstein on upgrading Spotify ahead of Q2 revenue miss
02:34pm, Tuesday, 29'th Jul 2025
Jason Helfstein, Oppenheimer head of internet research, joins 'The Exchange' to discuss Spotify as the stock sinks on Q2 revenue miss.
Oppenheimer says Carvana stock remains underestimated: find out more
01:57pm, Friday, 25'th Jul 2025
Carvana Co (NYSE: CVNA) has already rallied some 100% over the past three months – but an Oppenheimer analyst believes it still has significant further room to the upside.
Oppenheimer upgrades Spotify on long-term growth potential, sees 19% upside
10:32am, Thursday, 24'th Jul 2025
Spotify Technology S.A. has received a vote of confidence from Oppenheimer, with the firm citing the streaming giant's strong subscriber growth, expanding profit margins, and underutilized monetizatio
Oppenheimer's Jason Helfstein gives his read on Netflix's outlook post q2 earnings beat
12:06pm, Friday, 18'th Jul 2025
Jason Helfstein, Oppenheimer senior internet analyst, joins 'Money Movers' to discuss his takeaways from Netflix's q2 earnings.
CSG to Present at Oppenheimer's 28th Annual Technology, Internet & Communications Conference
08:30am, Wednesday, 16'th Jul 2025
DENVER--(BUSINESS WIRE)--CSG® (NASDAQ: CSGS) today announced that the company will present at Oppenheimer's 28th Annual Technology, Internet & Communications Conference on Monday, August 11th. The pr
Coinbase faces weak Q2 outlook, but long-term prospects intact, says Oppenheimer
01:54pm, Monday, 14'th Jul 2025
Coinbase Global is facing what analysts at Oppenheimer describe as an “unfavorable” setup heading into its second-quarter earnings report, with trading volumes and revenues expected to fall short
Oppenheimer Appoints Jon Hudson As Managing Director and Co-head of Healthcare Services Investment Banking
06:00am, Monday, 14'th Jul 2025
Veteran Dealmaker Brings More Than 25 Years of Healthcare Industry Experience NEW YORK , July 14, 2025 /PRNewswire/ -- Oppenheimer & Co. Inc. ("Oppenheimer"), a leading investment bank and wealth mana
Oppenheimer's Brian Schwartz sees more upside for Microsoft following record high
05:00pm, Wednesday, 09'th Jul 2025
Brian Schwartz, Oppenheimer analyst, joins 'Closing Bell Overtime' to talk Microsoft hitting record highs and why he is still bullish on the stock to continue higher from here.
Oppenheimer upgrades Microsoft as it sees AI potential not fully priced in
10:01am, Wednesday, 09'th Jul 2025
Oppenheimer has upgraded Microsoft (NASDAQ: MSFT) to Outperform from Perform, setting a price target of $600 per share- a nearly 21% increase from the company's closing price on Tuesday. The firm beli
Nike has internal, external challenges ahead, says Oppenheimer's Brian Nagel
04:59pm, Thursday, 26'th Jun 2025
CNBC's “Closing Bell” is joined by Oppenheimer's Brian Nagel to get his reaction to Nike's fiscal fourth-quarter earnings report.
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit
08:00am, Wednesday, 18'th Jun 2025
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that
